Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness
Dizziness, Vertigo, Vestibular Migraine
About this trial
This is an interventional treatment trial for Dizziness focused on measuring Vestibular weakness
Eligibility Criteria
Inclusion Criteria:
- Vertigo that has been present for at least 90 days, constant or predictable with attacks at least twice a week.
Classified as having vertigo from one of the following vestibulogenic vertigo conditions:
- Migraine Associated Vertigo, aka Vestibular Migraine
- Chronic Unilateral Vestibulopathy in one of three forms: Persistent Postural-Perceptual Dizziness (aka 3PD), Vestibular Neuritis, Labyrinthitis
- Score > 35 on Dizziness Handicap Inventory
- Willingness to cease vestibular suppressants for 24h prior to study.
Exclusion Criteria:
- Vertigo that first presented within the last 90 days
- Skull base surgery within the last 90 days
- Any skull implant (cochlear implant, bone conduction implant, DBS)
- Resolved vestibular dysfunction by the time of study appointment
- History of head injury within the last 6 months or currently suffering the effects of a head injury
- History of diagnosed untreated neuropsychiatric disorders (hypochondriasis, major depression, schizophrenia)
Prior documented neurodegenerative disorders of hearing and balance including:
- Multiple sclerosis
- Vestibular schwannoma
- History of Cerebrovascular disorders
- History of ear operation other than myringotomy (tube placement)
- Vitreous detachment of the retina (floaters) in the previous 90 days
- Presence of severe aphasia, and individuals who cannot provide informed consent
Sites / Locations
- Dizzy and Vertigo Institute of Los Angeles
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
No Intervention
OtoBand Efficacy on Vertigo and Dizziness
Placebo Device Efficacy on Vertigo and Dizziness
No Device
During the single site visit, participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand will be set to 92dB or 98dB bone conduction level (Re: 1 Dyne). The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
Participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand set to a bone conduction level 10dB lower than the level used in the experimental condition. Once fitted with the Otoband, participants will undergo the vestibular battery test. The investigator will record the outcome measurements.
Participants will wear the OtoBand, but turned off, to collect baseline data. This will be randomized. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.